Impaired elimination of caffeine in cirrhosis

Digestive Diseases and Sciences
P V DesmondS Schenker

Abstract

The effect of cirrhosis on the disposition and elimination of caffeine was examined. Caffeine (250 mg) was administered orally to 15 healthy controls and eight patients with cirrhosis. The elimination half-life was prolonged from 5.2 +/- 2.4 hr (mean +/- SD) in controls to 6.1 +/- 1.9 hr in cirrhotics, although this did not reach statistical significance. The plasma clearance, however, was significantly higher (1.4 +/- 0.5 ml/min/kg) in controls as compared to cirrhotics (0.9 +/- 0.3 ml/min/kg) (P less than 0.05). The plasma binding of caffeine was also lower in cirrhotics (31.3 +/- 1.8% vs 25.5 +/- 4.0%, P less than 0.01). The plasma clearance of unbound caffeine therefore was reduced from 2.0 +/- 0.7 ml/min/kg in controls to 1.2 +/- 0.4 ml/min/kg (P less than 0.01) in cirrhotics, demonstrating impaired elimination of caffeine in cirrhosis.

References

Jan 26, 1978·The New England Journal of Medicine·D RobertsonJ A Oates
Mar 1, 1979·Drugs·R K RobertsS Schenker
May 1, 1978·Chest·A MangioneW J Jusko
Jul 1, 1978·Clinical Pharmacology and Therapeutics·W D Parsons, A H Neims
Jan 1, 1975·Drug Metabolism Reviews·A W Burg
Oct 1, 1975·Clinical Pharmacology and Therapeutics·G R Wilkinson, D G Shand
Jul 8, 1976·The New England Journal of Medicine
Aug 1, 1968·Metabolism: Clinical and Experimental·S BelletE M Finck

❮ Previous
Next ❯

Citations

Jan 1, 1989·European Journal of Clinical Pharmacology·H WietholtzS Matern
Jan 1, 1981·European Journal of Clinical Pharmacology·H WietholtzR Preisig
Jan 1, 1991·European Journal of Clinical Pharmacology·T Zysset, H Wietholtz
Jan 1, 1991·European Journal of Clinical Pharmacology·H KraulA Hoffmann
Jan 4, 1989·Klinische Wochenschrift·A HolstegeW Gerok
Jan 1, 1994·Veterinary Research Communications·J SchumacherD C Ruffin
Jan 1, 1987·Pharmacology & Therapeutics·R JoeresE Richter
Jan 1, 1989·Baillière's Clinical Gastroenterology·P A Arns, R A Branch
Dec 1, 1995·Baillière's Clinical Gastroenterology·E L Renner
Nov 27, 1999·Molecular Aspects of Medicine·J A Hasler
Mar 22, 1984·The New England Journal of Medicine·A B BeckerF E Simons
Aug 1, 1991·Journal of Clinical Pharmacy and Therapeutics·A Sánchez-AlcarazG Sangrador
Oct 1, 1986·Clinical and Experimental Pharmacology & Physiology·J GeorgeL W Powell
Jan 1, 1988·Clinical and Experimental Pharmacology & Physiology·T L MurphyL W Powell
Oct 1, 1990·Alcoholism, Clinical and Experimental Research·S SchenkerG I Henderson
Feb 23, 2010·Clinical Pharmacokinetics·Trevor N JohnsonAmin Rostami-Hodjegan
Nov 4, 1985·Klinische Wochenschrift·T WangG Paumgartner
Dec 26, 2015·Regulatory Toxicology and Pharmacology : RTP·Duncan TurnbullGregory F Mariano
Mar 31, 2004·Journal of Clinical Pharmacology·Jadwiga Jodynis-LiebertJacek Juszczyk
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E RennerR Preisig
Feb 1, 1989·British Journal of Clinical Pharmacology·N R ScottM Y Morgan
Jan 1, 1993·Journal of Hepatology·A HolstegeW Gerok
Feb 17, 2015·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Richard CalvertPaddy Wiesenfeld
Sep 4, 2007·Sleep Medicine·William D S KillgoreThomas J Balkin
Aug 19, 2006·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Satoko OhfujiYoshio Hirota
Sep 2, 2008·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Kristina E PowlesTerrence D Ruddy
Dec 1, 1982·Journal of Pharmaceutical Sciences·J Blanchard
Oct 28, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gordon Jung-Hyuk ParkMeng Chong Ngu
Mar 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T C Peterson, C N Williams
Jun 1, 1996·Clinical Pharmacology and Therapeutics·C P DenaroN L Benowitz
Dec 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M HasegawaC Hirayama
Apr 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M L ShiffmanA Poklis
May 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R JoeresE Richter
Mar 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G JostR Preisig
Sep 20, 2018·European Journal of Drug Metabolism and Pharmacokinetics·Paschoalina RomanoElias David-Neto
Nov 1, 1985·Scandinavian Journal of Gastroenterology·A WahlländerR Preisig
Feb 1, 1994·Annals of Tropical Medicine and Parasitology·P WilairatanaS Wittayalertpanya

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
E RennerR Preisig
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
G JostR Preisig
© 2021 Meta ULC. All rights reserved